Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | G6PD | P11413 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8786755 | 0.85 | CYP4F2 (0.60) | SMN1; SMN2TP53RXFP1CYP2A6ALDH1A1 | |
| SCHEMBL1470493 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2TP53RXFP1PKMCYP2A6 | |
| SCHEMBL14564345 | 0.84 | LMNA (0.50) | SMN1; SMN2TP53RXFP1PKMALDH1A1 | |
| SCHEMBL7441306 | 0.83 | CYP2A6 (0.47) | SMN1; SMN2TP53RXFP1PKMCYP2A6 | |
| SCHEMBL19627156 | 0.82 | CA2 (0.49) | SMN1; SMN2TP53RXFP1PKMMAPT | |
| SCHEMBL2083362 | 0.82 | EGFR (0.48) | SMN1; SMN2PKMALDH1A1MAPTPOLB | |
| SCHEMBL6964040 | 0.81 | CYP2A6 (0.56) | SMN1; SMN2TP53RXFP1CYP2A6MAPT | |
| SCHEMBL3922001 | 0.81 | GAA (0.42) | SMN1; SMN2TP53RXFP1PKMALDH1A1 | |
| SCHEMBL10982988 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2PKMALDH1A1MAPTPOLB | |
| SCHEMBL8605002 | 0.80 | MTNR1A (0.55) | SMN1; SMN2TP53RXFP1PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-10 | — | — | US | disclosed |
| WO-2021083060-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2021-05-06 | — | — | WO | disclosed |
| US-20210115031-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| WO-2021047674-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | 南京明德新药研发有限公司 | 2021-03-18 | — | — | WO | disclosed |
| EP-0761666-A2 | Antidepressant 1-arylalkyl-4-(alkoxypyridinyl)- or 4-(alkoxypyrimidinyl)piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-12 | — | — | EP | disclosed |
| EP-0267794-B1 | PROCESS FOR PREPARING POLYOLEFINS | Nippon Petrochemicals Co., Ltd. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0422119-A4 | BENZOTHIOPHENE DERIVATIVES USEFUL FOR MODIFYING FEEDING BEHAVIOR AND OBSESSIVE-COMPULSIVE BEHAVIOR | — | 1991-11-13 | — | — | EP | disclosed |
| EP-0422119-A1 | BENZOTHIOPHENE DERIVATIVES USEFUL FOR MODIFYING FEEDING BEHAVIOR AND OBSESSIVE-COMPULSIVE BEHAVIOR | NEUREX CORPORATION (US) | 1991-04-17 | — | — | EP | disclosed |
| WO-1989012447-A1 | BENZOTHIOPHENE DERIVATIVES USEFUL FOR MODIFYING FEEDING BEHAVIOR AND OBSESSIVE-COMPULSIVE BEHAVIOR | NEUREX CORPORATION (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0267794-A2 | Process for preparing polyolefins | Nippon Petrochemicals Co., Ltd. (JP) | 1988-05-18 | — | — | EP | disclosed |
| US-4525555-A | TITANIUM COMPOUND SUPPORTED ON SOLID REACTION PRODUCT OF MAGNESIUM HALIDE, SILOXANES, ORGANIC COMPOUNDS | NIPPON OIL COMPANY, LIMITED (JP) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | SMN1; SMN2 2827/4885TP53 1333/4885RXFP1 1221/4885 |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | STING1, CGAS, IRF3 | SMN1; SMN2 3821/4885TP53 944/4885RXFP1 918/4885 |
| US-20210115031-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER4, PTGER1, PTGER2 | SMN1; SMN2 4477/4885TP53 1311/4885RXFP1 215/4885 |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | PTGER4, PTGER1, PTGER2 | SMN1; SMN2 4477/4885TP53 1311/4885RXFP1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.